biotech / news / / Seeking Alpha
Eli Lilly (LLY) and Novo Nordisk (NVO) surged Thursday morning after the US FDA proposed placing a significant restriction on the ability of pharmacies to make compounded versions of GLP-1.
The US FDA proposed significant restrictions on pharmacies compounding GLP-1 weight loss drugs.
KEY POINTS
- Eli Lilly and Novo Nordisk stocks surged following the FDA's proposed compounding restrictions.
- The FDA's move directly targets pharmacies making non-branded versions of GLP-1 medications.
- These proposed FDA restrictions could further solidify the market dominance of LLY and NVO.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →